IBDEI3A0 ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,52286,2)
 ;;=^5002659
 ;;^UTILITY(U,$J,358.3,52287,0)
 ;;=E11.638^^193^2527^29
 ;;^UTILITY(U,$J,358.3,52287,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,52287,1,3,0)
 ;;=3^DM Type 2 w/ Oth Oral Compl
 ;;^UTILITY(U,$J,358.3,52287,1,4,0)
 ;;=4^E11.638
 ;;^UTILITY(U,$J,358.3,52287,2)
 ;;=^5002660
 ;;^UTILITY(U,$J,358.3,52288,0)
 ;;=E11.641^^193^2527^20
 ;;^UTILITY(U,$J,358.3,52288,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,52288,1,3,0)
 ;;=3^DM Type 2 w/ Hypoglycemia w/ Coma
 ;;^UTILITY(U,$J,358.3,52288,1,4,0)
 ;;=4^E11.641
 ;;^UTILITY(U,$J,358.3,52288,2)
 ;;=^5002661
 ;;^UTILITY(U,$J,358.3,52289,0)
 ;;=E11.649^^193^2527^21
 ;;^UTILITY(U,$J,358.3,52289,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,52289,1,3,0)
 ;;=3^DM Type 2 w/ Hypoglycemia w/o Coma
 ;;^UTILITY(U,$J,358.3,52289,1,4,0)
 ;;=4^E11.649
 ;;^UTILITY(U,$J,358.3,52289,2)
 ;;=^5002662
 ;;^UTILITY(U,$J,358.3,52290,0)
 ;;=E11.65^^193^2527^17
 ;;^UTILITY(U,$J,358.3,52290,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,52290,1,3,0)
 ;;=3^DM Type 2 w/ Hyperglycemia
 ;;^UTILITY(U,$J,358.3,52290,1,4,0)
 ;;=4^E11.65
 ;;^UTILITY(U,$J,358.3,52290,2)
 ;;=^5002663
 ;;^UTILITY(U,$J,358.3,52291,0)
 ;;=E11.69^^193^2527^32
 ;;^UTILITY(U,$J,358.3,52291,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,52291,1,3,0)
 ;;=3^DM Type 2 w/ Oth Spec Compl
 ;;^UTILITY(U,$J,358.3,52291,1,4,0)
 ;;=4^E11.69
 ;;^UTILITY(U,$J,358.3,52291,2)
 ;;=^5002664
 ;;^UTILITY(U,$J,358.3,52292,0)
 ;;=E11.8^^193^2527^34
 ;;^UTILITY(U,$J,358.3,52292,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,52292,1,3,0)
 ;;=3^DM Type 2 w/ Unspec Compl
 ;;^UTILITY(U,$J,358.3,52292,1,4,0)
 ;;=4^E11.8
 ;;^UTILITY(U,$J,358.3,52292,2)
 ;;=^5002665
 ;;^UTILITY(U,$J,358.3,52293,0)
 ;;=E11.9^^193^2527^35
 ;;^UTILITY(U,$J,358.3,52293,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,52293,1,3,0)
 ;;=3^DM Type 2 w/o Complications
 ;;^UTILITY(U,$J,358.3,52293,1,4,0)
 ;;=4^E11.9
 ;;^UTILITY(U,$J,358.3,52293,2)
 ;;=^5002666
 ;;^UTILITY(U,$J,358.3,52294,0)
 ;;=E11.29^^193^2527^27
 ;;^UTILITY(U,$J,358.3,52294,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,52294,1,3,0)
 ;;=3^DM Type 2 w/ Oth Diab Kidney Compl
 ;;^UTILITY(U,$J,358.3,52294,1,4,0)
 ;;=4^E11.29
 ;;^UTILITY(U,$J,358.3,52294,2)
 ;;=^5002631
 ;;^UTILITY(U,$J,358.3,52295,0)
 ;;=E11.311^^193^2527^14
 ;;^UTILITY(U,$J,358.3,52295,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,52295,1,3,0)
 ;;=3^DM Type 2 w/ Diab Rtnop w/ Macular Edema
 ;;^UTILITY(U,$J,358.3,52295,1,4,0)
 ;;=4^E11.311
 ;;^UTILITY(U,$J,358.3,52295,2)
 ;;=E11.319^5002632
 ;;^UTILITY(U,$J,358.3,52296,0)
 ;;=E11.319^^193^2527^15
 ;;^UTILITY(U,$J,358.3,52296,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,52296,1,3,0)
 ;;=3^DM Type 2 w/ Diab Rtnop w/o Macular Edema
 ;;^UTILITY(U,$J,358.3,52296,1,4,0)
 ;;=4^E11.319
 ;;^UTILITY(U,$J,358.3,52296,2)
 ;;=^5002633
 ;;^UTILITY(U,$J,358.3,52297,0)
 ;;=E11.3211^^193^2527^22
 ;;^UTILITY(U,$J,358.3,52297,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,52297,1,3,0)
 ;;=3^DM Type 2 w/ Mild Nonp Rtnop w/ Macular Edema,Rt Eye
 ;;^UTILITY(U,$J,358.3,52297,1,4,0)
 ;;=4^E11.3211
 ;;^UTILITY(U,$J,358.3,52297,2)
 ;;=^5138331
 ;;^UTILITY(U,$J,358.3,52298,0)
 ;;=E11.3212^^193^2527^23
 ;;^UTILITY(U,$J,358.3,52298,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,52298,1,3,0)
 ;;=3^DM Type 2 w/ Mild Nonp Rtnop w/ Macular Edema,Lt Eye
 ;;^UTILITY(U,$J,358.3,52298,1,4,0)
 ;;=4^E11.3212
